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1001-22 Urine and Plasma Matrix Metalloproteinase 9 and 2 
Levels in Patients With Coronary Artery Disease
Patrick Fitzsimmons, Mark E. Lawrence, Reza Forough, Brian Weylie, D. Scott Gantt, 
Gregory J. Dehmer, Scott & White Clinic, Temple, TX, Texas A&M College of Medicine, 
College Station, TX
Background: Matrix metalloproteinases (MMPs) are implicated in developing atheroscle-
rosis. Urine (U) MMPs have not been previously evaluated.
Methods: U and plasma (P) MMP9 and MMP2 were measured in 3 groups: ACS =
patients (pts) with elevated troponin-I or angiographic findings of a ruptured plaque. Cor-
onary artery disease (CAD) = pts with CAD, but no clinical instability. Healthy volunteers
(HV) were < 35 years of age with no risk factors for CAD; angiography was not performed
in HV. We set the upper limit of normal as the mean + 2 standard deviations.
Results: The upper limits of normal were: UMMP9 = 0.14 ng/ug protein, UMMP2 = 0.24
ng/ug protein, PMMP9 = 712 ng/ml, PMMP2 = 355 ng/ml. The percent with elevated val-
ues is shown in the table. The percent of pts with elevated U or P MMP2 was higher
(p<0.01) in the ACS and CAD groups. There was a similar trend (p<0.07) in MMP9 levels,
but no difference in the percent of pts with elevated MMP9 or MMP 2 levels between
those with CAD and ACS.
Conclusion: The percent of pts with elevated U and P MMP2 levels was higher in those
with CAD compared to healthy volunteers, and a similar trend existed for MMP9. How-
ever, the percent of pts with elevated MMP9 and MMP2 in P or U was not different in
those with ACS compared with stable CAD. These data suggests that MMP levels may
be a ubiquitous marker of atherosclerosis with U levels appearing to identify more pts
than a blood sample. However, because elevated MMPs may be due to atherosclerosis
at any location, their usefulness for identifying ACS may be limited.
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1001-23 Calmodulin Kinase Inhibition Improves Survival in 
Calcineurin Transgenic Mice
Michelle S. Khoo, Rong Zhang, Chad E. Grueter, Gemin Ni, Martha A. Bass, Jinying 
Yang, Lisa A. Mendes, Eric N. Olson, Roger J. Colbran, Mark E. Anderson, Vanderbilt 
University Medical Center, Nashville, TN, University of Texas Southwestern Medical 
Center, Dallas, TX
Background: Transgenic (TG) mice expressing constitutively active calcineurin (CAN)
develop severe cardiomyopathy and die prematurely. We previously reported that calm-
odulin kinase (CaMK) activity is increased in CAN TG mice and pharmacological CaMK
inhibition effectively suppressed ventricular arrhythmias.
Methods: We developed TG mice with cardiac expression of a specific CaMK inhibitory
peptide, IP, and control mice that express an inactive scrambled peptide, CP. CAN TG
mice were crossed with IP TG and CP TG mice to test for functional interaction between
CAN and CaMK signaling.
Results: Ventricular homogenates from age- and gender-matched CAN-IP TG mice
showed a trend toward reduced CaMK activity compared to CAN-CP mice (3.18 ± 0.20
vs. 4.39 ± 0.50 nmol/min/mg; n = 10 each group; P = 0.07). Echocardiography in con-
scious mice at 50 days showed significant preservation of left ventricular (LV) fractional
shortening (FS) in CAN-IP TG mice (FS = 47.8 ± 1.9%, n = 11) compared to CAN-CP TG
mice (FS = 32.0 ± 1.2%, n = 10; P < 0.001). CAN-IP TG mice had improved survival com-
pared with CAN-CP TG mice (Figure). We followed 2 cohorts of 30 CAN-IP and 30 CAN-
CP TG mice. At eight months, 12 CAN-CP mice had died suddenly but only 4 CAN-IP TG
mice died (P = 0.04).
Conclusion: These results indicate that CaMK activity is critical to the pathology of CAN
cardiomyopathy and show CaMK inhibition can be a successful therapeutic intervention
in CAN cardiomyopathy by reducing arrhythmias, preserving LV function and improving
mortality.
Noon
1001-24 Long-Term Follow-Up of Safety and Feasibility of 
Autologous Skeletal Myoblast Transplantation in 
Patients Undergoing Coronary Artery Bypass Graft 
Surgery
Nabil Dib, Dean Kereiakes, Patrick McCarthy, Jonathan Dinsmore, W. Robert MacLellan, 
Gregg Fonarow, Robert Michler, Diane Buchele, Philip Binkley, Shaun Opie, Amir 
Gahremanpour, Sean Kane, Marwan Ghazoul, Edward Diethrich, Arizona Heart Institute, 
Phoenix, AZ, Diacrin, Inc., Charlestown, MA
Background: Autologous myoblast transplantation (AMT) to repair myocardial infarction
has been shown to be safe and effective in preclinical studies. The objective of this study
was to demonstrate the safety and feasibility of myoblast transplantation in humans.
Methods: Patients scheduled to undergo elective coronary artery bypass grafting
(CABG) were enrolled in the US multicenter clinical trial over a 2-year period. Subjects
with previous myocardial infarction and a left ventricular ejection fraction < 40 were eligi-
ble to participate. A skeletal muscle biopsy of approximately 2 grams was excised from
each patient to isolate and expand myoblasts over 2-5 weeks. Between 3 and 30 direct
injections of myoblasts were delivered into the area of infarction using one of 4 escalating
doses ranging from 10 to 300 million cells. Pre and post-injection ECG, echocardiogram,
Holter monitoring, positron emission tomography (PET) and magnetic resonance imag-
ing (MRI) were performed.
Results: Eighteen patients underwent AMT combined with CABG. The mean age of
patients was 54 years. The average baseline ejection fraction (EF) was 26 %. Purity of
the cells ranged from 47% to 98% CD56+myoblasts. The cells were delivered in all sub-
jects without any perioperative complications. Three serious adverse events occurred;
one death due to graft occlusion and two episodes of ventricular tachycardia, 1 non-sus-
tained and 1 sustained, in the first 2 weeks post-operatively. Echocardiography, PET and
MRI scans showed evidence of viability in the area of grafted scar. The mean EF of 10
patients improved from 24.8% to 33.9% in (p=0.04).
Conclusion: Results of the first US study indicate that AMT in patients undergoing CABG
is feasible and safe. Improvement in viability and wall thickness is encouraging and war-
rants future clinical trials evaluating the effect of AMT on left ventricular function. Com-
plete follow-up results will be presented.
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1001-25 Primary Results of the Rapid Emergency Department 
Heart Failure Outpatient Trial (REDHOT): A Multicenter 
Trial Examining B-Type Natriuretic Peptide Levels, 
Emergency Physician Decision Making and Outcomes 
in Patients Presenting With Shortness of Breath
Alan S. Maisel, Judd Hollander, David Guss, Peter McCullough, Richard Nowak, Gary 
Green, Mitchell Saltzberg, Radmilia Kazanegra, Paul Clopton, Robert Jesse, The 
REDHOT Investigators, Veteran's Affairs Medical Center, San Deigo, CA, University of 
California, San Diego, CA
Background: The vast majority of patients seen in the Emergency Department (ED) with
CHF are admitted to the hospital, leading to exorbitant costs & resource utilization. There
are few tools that aid physicians in decision making with regard to ED treatment followed
by discharge vs immediate or delayed hospitalization. BNP correlates with the presence
of CHF, disease severity and prognosis.This is the first large cohort that examines BNP in
relation to physician decision making, patient disposition, and critical outcomes in emer-
gency medicine. Methods: In this10 center trial, patients seen in the ED with shortness of
breath were consented to have BNP levels drawn on arrival, every 3 hrs in the ED & at
the time of admission or discharge. Physicians were only told whether the initial BNP
level was greater or less than 100 pg/ml, & blinded to subsequent BNP levels. Patients
were followed up for 90 days after discharge. Results: Of the 504 patients consented,
90% were hospitalized, even though only 68% were designated for hospitalization upon
initial evaluation. 66% of patients who were admitted with a NYHA classification of III or
IV had BNP levels < 200 pg/ml (11% of total population). This group had a 90-day mortal-
Percent of Patients with Elevated MMP Levels
UMMP9 UMMP2 PMMP9 PMMP2
ACS (n=33) 27.3% 45.4% 25.0% 7.2%
CAD (n=60) 36.7% 48.3% 28.0% 28.0%
HV (n=15) 6.7% 6.7% 0% 0%
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ity of only 2%. 36 patients were discharged from the ED with a BNP level > 400 pg/ml.
The 90 days mortality was 9% in this group, while patients discharged from the ED with a
BNP level < 400 pg/ml had 0% mortality at 90 days. Patients who were discharged home
from the ED actually had higher BNP levels than those admitted (976 versus 767, p=0.6).
Using regression analysis, ED doctor’s intention to admit or discharge a patient had no
influence on their 90 day mortality, while the BNP level was a strong predictor of 90 day
mortality. Conclusion: In patients presenting to the ED with heart failure, there is a strong
disconnect between the perceived severity of CHF by ED physicians and severity as
determined by BNP levels. The results of this study strongly suggests that BNP levels will
aid physicians in making appropriate triage decisions about whether to admit or dis-
charge patients. This should avoid prolonged stays in the ED, unnecessary hospitaliza-
tions, inappropriate discharges home and lead to better patient care.
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1001-26 Exchange of Beta-Blocking Therapy in Heart Failure 
Patients. Experiences From the Post Study Phase of 
COMET (the Carvedilol or Metoprolol European Trial)
Andrea Di Lenarda, Philip A. Poole-Wilson, John G. Cleland, Peter Hanrath, Michel 
Komajda, Jacobus Lubsen, Beatrix Lutiger, Marco Metra, Willem J. Remme, Armin 
Scherhag, Andrew Charlesworth, Christian Torp-Pedersen, For the COMET 
investigators, Ospedale di Cattinara, Trieste, Italy, National Heart and Lung Institute, 
London, United Kingdom
Background: The COMET study reported a survival benefit for Carvedilol (C), a β1, β2
and α1 blocking agent, versus Metoprolol (M), a β1 selective blocker, in 3029 patients
(pts) (NYHA class II-IV, LVEF < 35%) with chronic heart failure (HF) followed-up for 46-74
months. While withdrawal of β-blockade (BB) is associated to worsening HF and arrhyth-
mias, only limited information exists on exchanging BB in pts with HF.
Methods: At the end of COMET, study BB therapy in pts with stable HF was to be
stopped without unblinding and down-titration and immediately replaced by open BB at a
dose equivalent to half of the study dose of pts. Thereafter, up-titration to maximum-toler-
ated or target BB dose was recommended. Pts were followed for 30 days for adverse
events.
Results: 1429 pts (47.2%) completed COMET on study BB (C 41 ± 15 mg, M 82 ± 30
mg). 1321 (92.4%) were subsequently switched to a post-study BB (1014 pts, 76.8%, to
C; 201, 15.2%, to M and 102, 7.7%, to bisoprolol), while 108 pts (7.6%) withdrew BB. Pts
staying on the same BB (8.7% on C, 7.4% on M) reported less adverse events than pts
switched to a different BB (15.1% from C to M, 14.1% from M to C) or those who with-
drew BB (22.2%). Most events occurred in the first week after the transition. The rate of
serious events was lower in pts who stayed on C (2.1%) or on M (3.2%), or in pts chang-
ing from M to C (3.1%), while higher in those switched from C to M (9.4%) or withdrawing
BB (11.1%). Nine pts (0.6%) died, 2 (0.2%) on C, 5 (2.5%) on M and 2 (1.9%) not receiv-
ing open BB. HF related events were more frequent in those switching from C to M
(4.7%; 4.7% serious) than in pts changing from M to C (2.3%; 1.5% serious). Bradycardia
and hypotension were reported in < 1% of pts. Pts on M who were switched to a reduced
dose of C (35%) showed a rate of HF events similar to those patients staying on C, but
lower than those changing to fully equivalent dose C (65%).
Conclusion: The exchange of BB without down-titration is a practical, safe and well-tol-
erated strategy in stable HF. The transition from M to a reduced dose of C is associated
with the lowest rate of serious and HF related events. Pts on M can be safely switched to
C to benefit from the survival advantage demonstrated in the COMET study.
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1001-27 Patients at Risk for Recurrent Embolism After 
Percutaneous Closure of Patent Foramen Ovale for 
Presumed Paradoxical Embolism
Markus Schwerzmann, Andreas Wahl, Krassen Nedeltchev, Thilo Heimes, Giorgio 
Moschovitis, Heinrich P. Mattle, Christian Seiler, Bernhard Meier, Stephan Windecker, 
Swiss Cardiovascular Center Bern, Bern, Switzerland
Background: Percutaneous closure of a patent foramen ovale (PFO) is an alternative to
medical or surgical prevention of recurrent embolism in patients with presumed PFO
mediated paradoxical embolism. Risk factors for recurrence after successful PFO closure
have not been completely elucidated yet.
Methods: We followed 299 patients with presumed PFO mediated paradocixal embolism
after percutaneous PFO closure for a total of 662 patient-years (mean follow-up: 2.2
years, range 0.2 – 8.5 years), assessing postprocedural shunt, recurrent embolic events
and device-related morbidity. Freedom of recurrence was calculated according to the
Kaplan-Meier method. Predictors of recurrence were calculated using a Cox proportional
hazard model.
Results: Twenty recurrent embolic events were observed (14 transient ischemic attacks,
5 events of peripheral embolism, 1 stroke), resulting in an actuarial recurrence rate of
3.8% (95% CI 1.7-6.4%) at 1 year, 7.9 (95% CI 4.9-12.6) at 2 years, and 8.7 (95% CI 5.5-
13.7%) at 4 years. Univariate predictors of recurrence were age at implantation > 60
years (hazard ratio 2.7, 95% CI 1.1-6.5), cardiovascular risk factors (hazard ratio 1.5 for
every additional factor, 95% CI 1.05-2.1), and most importantly the number of embolic
events prior to PFO closure (> 2 events: hazard ratio 4.1, 95% CI 1.7-9.8). Since patients
with multiple embolic events prior to PFO closure were older, only the cardiovascular risk
profile and > 2 events prior to PFO closure remained significant predictors of recurrence
in a multivariate Cox proportional hazard analysis. There was no relation between recur-
rence rate and atrial septal anatomy (PFO with or without atrial septal aneurysm), gen-
der, residual shunt after 6 months, type or size of device, and embolic index
event.Conclusions: Patients with > 2 thromboembolic events prior to device implantation
and patients with multiple cardiovascular risk factors are at increased risk for recurrence
of embolic events after PFO closure. These findings suggest that alternative mechanisms
in addition to paradoxical embolism may be present in this patient group.
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1001-28 Chronotropic Incompetence in Children With Late 
Postoperative Atrial Flutter: A Case-Control Study
Nitasha Anand, Brian W. McCrindle, Gil J. Gross, Hospital for Sick Children, Toronto, ON, 
Canada
Background: Atrial flutter (AF) causes late postoperative (postop) morbidity in congeni-
tal heart patients. Sinoatrial node dysfunction (SAND) is often present but has not been
systematically evaluated as an AF risk factor. Methods: An institutionally approved retro-
spective single-center case-control study was performed. A computerized cardiology
database search identified patients aged <18 years with documented late AF (>6 months
postop; excluded if AF present at 1-6 months), and with >1 graded exercise test (GXT)
and/or 24-hour outpatient ambulatory ECG (Holter). AF-free controls were matched for
surgical procedures and year of birth ± 3 (median difference 0.4) years, with postop fol-
low-up at least equivalent to time points of first AF documentation in corresponding
cases. Non-AF heart rate (HR) data were extracted from all GXT (median 2/case, 2/con-
trol) and Holter (2/case, 1/control) records. Percent of maximum (max) predicted HR
achieved (%pred) was based on HRmax/(220 – age in years), where HRmax = max HR on
GXT or Holter. Data were analyzed using mixed linear regression for repeated measures.
Results: There was 85% concordance for 125 open heart operations in 42 case-control
pairs. AF onset in cases was at age 9.4±5.0 (mean±SD) years. Cases had lower average
HR, max HR, and %pred than controls (Table). Conclusion: Chronotropic reserve is
reduced but minimum HR is similar in AF patients versus controls. Chronotropic incom-
petence is thus an important feature of SAND in patients with late postop AF. 
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1001-29 Impact of Gender on Long-Term Mortality in 4,234 
Women and 6,898 Men Evaluated With Exercise and 
Dobutamine Stress Echocardiography
Leslee J. Shaw, Charles Vassey, Stephen Sawada, Curtis M. Rimmerman, Thomas H. 
Marwick, American Cardiovascular Research Institute, Atlanta, GA
Background. Prior research is limited regarding the diagnostic and prognostic accuracy
of cardiac imaging modalities in women. The purpose of the current report was to exam-
ine 5-year mortality in 4,234 women and 6,898 men undergoing exercise or dobutamine
stress echocardiography at 3 hospitals.
Methods. Univariable and multivariable Cox proportional hazards models were used to
estimate time to cardiac death in this multicenter, observational registry.
Results. In this cohort of 11,132 patients, women had a greater frequency of cardiac risk
factors (p<0.0001). However, men more often had a history of coronary disease including
a greater frequency of stress-induced ischemia (p<0.0001). During the 5 years of follow-
up, 103 women and 226 men died from coronary artery disease (p<0.0001). From the
echocardiographic examination, estimates of left ventricular function (p<0.0001) and the
extent of ischemia (p<0.0001) noted during peak stress were highly predictive of cardiac
death. At 5 years, risk-adjusted survival was 99.4%, 97.6%, and 95% for exercising
women with no, single, and multiple vascular territories with ischemia (p<0.0001). For
women undergoing dobutamine stress, 5-year survival was 95%, 89%, and 86.6% for
those with no, 1, and 2 or 3 vessel ischemia (p<0.0001). For exercising men, cardiac
death at 5 years was higher at 1.1% to 4.5% for 0 to 3 vessel ischemia (p<0.0001). Sig-
nificantly worsening cardiac survival was noted for the 1,568 men undergoing dob-
utamine stress echocardiography (p<0.0001). No inducible ischemia was associated with
a 92% survival as compared with cardiac death rates of >16% for men with ischemia on
dobutamine stress echocardiography (p<0.0001).
Conclusion. Echocardiographic measures of inducible wall motion abnormalities and
global and regional left ventricular function are highly predictive of long term outcome for
women and men, alike.
Table
Minimum HR 
(Holter, beats/
min)
Average HR 
(Holter, beats/
min)
Max HR (GXT and 
Holter, beats/min)
%pred
Case (N=42) 55 ± 18 76 ± 10 146 ± 31 70 ± 15
Control 
(N=42)
56 ± 14 83 ± 17 169 ± 22 81 ± 10
P NS <0.001 <0.0001 <0.0001
